Closed Session

Appendix 1

Research group of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease

Closed Session, 11 October 2004

Provisional Agenda

Original Paper ref. 1 Opening of the Session and Adoption of the Agenda 2 Papers for adoption - post-Gerzensee working groups 2.1 Biosecurity working group Haas/Sanchez- 2a

Viscaino

i. Paper for adoption: Minimum requirements for FMD serology laboratories 2.2 Diagnostic reagent bank ii. For adoption: EUFMD Position paper Bernd Haas 2b

2.3 Sample transport 2.3.1 For adoption: Guidelines paper Vilmos Palfi 2c

3 Progress reports- post-Gerzensee working groups 3.1 Assisted delivery of samples from third countries Secrt.

3.2 Vaccine selection for the European banks

David Paton

3.2.1 Related issues - the OIE ad hoc group on vaccine and antigen banks 3.2.2 Global FMD mapping/modelling - surveillance for circulating strains

Secrt.

3.3 Comparative evaluation of candidate DIVA tests 3.3.1 Findings and recommendations of the Improcon/EUFMD/EC Brescia workshop Kris de Clercq 3.4 Post-vaccination surveillance 3.4.1 Gerzensee issues: within herd prevalence estimates, NSP test performance Matthias Greiner

3.4.2 New EC Directive: is compliance with PVS requirements technically feasible? 3.5 FAO Phase XVIII progress and plan

3.6 Proficiency panel for virus detection; progress report (pilot study) 3.7 Pen-side tests –evaluation/guidelines on use

3.8 Laboratory contingency planning

Paton/De Clercq/Dekker

3f

David Paton 3h

David Paton 3i

Sammin, Unal, Bulut Secret.

3.9 Virus inactivation kinetics Alexandersen 3l 3.10 Laboratory sero-diagnostic capacity 3.11 Bio-security working group

4 Short report of EUFMD/EC supported studies relating to validation of DIVA tests 4.1 Prevalence in vaccinated herds exposed to infection –Israel Hagai Yadin 4n

4.2 Collection of sera/specimens for DIVA test validation –

SAT viruses Donal Sammin

5 Items arising from the Executive Committee 69th and 70th Sessions 5.1 Performance of new oil adjuvanted vaccine and conventional vaccines produced by the SAP Institute in 2004

Nilay Unal

5.2 Guidelines for monitoring performance of vaccines and vaccination in the field Hagai Yadin 5q

5.3 Terms of Reference/Vision for the Research group of the Standing Technical Committee

6 Items arising from EUFMD implemented actions in FMD Control in TransCaucasus under EC support 6.1 Plan for assessment of potency, and induction of NSP antibodies by FMD vaccines produced in Armenia and Georgia Secret. 5r

Haas, Secret.

7 Items raised by the Committee members 7.1 National responses to new Directive: expert groups/simulation exercises

8 Upcoming issues and items for consideration in new workplan

9 Workplan of the EUFMD Research Group to mid-2005

10 EUFMD Research Group Sessions in 2005 and 2006